SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oncothyreon
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (2246)8/22/2013 10:48:01 AM
From: scaram(o)uche  Read Replies (2) of 2344
 
Out today, seems like it was written some time ago?

>> It's unclear how many subgroup analyses were planned (is this 1 of 100 that happened to hit?) <<

Four, not 100. Four, not 40.

Four!

>> the new class of anti- PD-1 and PDL-1 immunotherapies in development at Roche, Merck (MRK), and Bristol Myers (BMY) may make Stimuvax obsolete before it even hits the market <<

Unless this guy is one of the two individuals who I've seen make this argument previously, there are now THREE morons out there floating the same bull.

1. Combine ipi and PD1 targeted therapy and you can't do better than 50% in melanoma, which some consider the best bet for immunotherapy, and

2. Responses ain't cures.

Fact? The ipi and pd1 gangs will be looking for good vaccines with which to pair their therapies.

Thanks, Nigel.

Best! Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News